Easier access to compassionate end-of-life care is now available for patients and families in Fort Worth and surrounding ...

Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009: Full Topline Phase 2 Data in Acute Myeloid Leukemia and FDA Regulatory Review Expec ...

State Street Corp raised its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) by 30.2% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 174,529 shares of the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.93% of ...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totalling ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ: NASDAQ:SLS), a biopharmaceutical company specializing in cancer therapies, has reached a significant milestone in its Phase 3 REGAL clinical trial ...